Skip to Content

'
Srdan Verstovsek, MD, PhD

Present Title & Affiliation

Primary Appointment

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1994 Faculty for Natural Sciences, University of Zagreb, Zagreb, Croatia, PHD, Natural Sciences
1992 School of Medicine, University of Zagreb, Zagreb, Croatia, MD, Medicine

Board Certifications

2002 Oncology Board Certification
1998 Internal Medicine Board Certification

Experience/Service

Other Appointments/Responsibilities

Chief, Section for Myeloproliferative Neoplasms, Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-present
Director, Clinical Research Center for Myeloproliferative Neoplasms, Leukemia Dept., The University of Texas MD Anderson Cancer Center, Houston, TX, 2012-present
Medical Advisory Board Member, American Partnership for Eosinophilic Disorders, N/A, 2009-present
Medical Advisory Board Member, The Mastocytosis Society, N/A, 2005-present
Medical Advisory Board Member, The Chronic Myeloproliferative Disorders Education Foundation, N/A, 2005-present
Executive Committee Member, International Working Group for Myelofibrosis Treatment and Research (IWG-MTR), N/A, 2005-present
Graduate Faculty, Graduate School of Biological Sciences, University of Texas, Houston, TX, 2003-2008

Consultantships

Ziopharm, Inc, Boston, 4/2005-12/2008

Institutional Committee Activities

Member, Institutional Animal Care and Use Committee, The University of Texas MD Anderson Cancer Center, 8/2006-12/2006
Member, Faculty Senate for the Department of Leukemia, The University of Texas MD Anderson Cancer Center, 9/2005-9/2008
Member, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 9/2005-9/2008
Member, Clinical Research Committee I, The University of Texas MD Anderson Cancer Center, 9/2003-9/2006

Honors and Awards

2013 Distinguished Lecturer Award, Society of Hematologic Oncology
2013 Irwin H. Krakoff Award for Excellence in Clinical Research, Division of Cancer Medicine Faculty Achievement Award, The University of Texas MD Anderson Cancer Center
2011 Distinguished Alumnus Award, Division of Cancer Medicine Hematology/Oncology Fellowship Program, The University of Texas MD Anderson Cancer Center
2010 Celgene 2010 Young Investigator Award for Clinical Research in Hematology
2009 Marshall Heritage Foundation
2007 North Star Charitable Foundation
2006 Cancer Treatment and Research Award
2005 Chambers Medical Foundation Award, 2005
2005 The Joe W. and Dorothy Dorsett Brown Foundation Award
2002 Ronald Cates Memorial Fund for Leukemia
2001 Achievement in Cancer Research Award, The University of Texas MD Anderson Cancer Center, Division of Medicine, Fellowship Program
1989-1991 Travel Award for Scientific Training, Croatian Ministry of Science

Professional Memberships

American Association for Cancer Research
Member, 2003-present
American Medical Association
Member, 2005-present
American Society of Clinical Oncology
Member, 1999-present
American Society of Hematology
Member, 2004-present
European Hematology Association
Member, 2002-present
HemOnc Today Editorial Board
Editor, 5/2014-present
Society of Hematologic Oncology
Education Committee, 1/2015
Member, 2013

Selected Publications

Peer-Reviewed Original Research Articles

1. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372(5):426-35, 1/2015. PMID: 25629741.
2. Verstovsek S, Levine RL, Stein BL. Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis. Clin Lymphoma Myeloma Leuk 14(6):e229, 12/2014. e-Pub 11/2014. PMID: 25439106.
3. Verstovsek S, Hoffman R, Mascarenhas J, Soria J, Bahleda R, McCoon P, Tang W, Cortes J, Kantarjian H, Ribrag V. A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis. Leuk Res. e-Pub 11/2014. PMID: 25530567.
4. Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek S. ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia 28(10):2090-2, 10/2014. e-Pub 5/2014. PMID: 24854988.
5. Daver N, Shastri A, Kadia T, Newberry K, Pemmaraju N, Jabbour E, Zhou L, Pierce S, Cortes J, Kantarjian H, Verstovsek S. Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leuk Res 38(9):1126-9, 9/2014. e-Pub 7/2014. PMCID: PMC4157096.
6. Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH. Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 7/15/2014. PMID: 25107338.
7. Wang L, Zhang H, Rodriguez S, Cao L, Parish J, Mumaw C, Zollman A, Kamoka MM, Mu J, Chen DZ, Srour EF, Chitteti BR, HogenEsch H, Tu X, Bellido TM, Boswell HS, Manshouri T, Verstovsek S, Yoder MC, Kapur R, Cardoso AA, Carlesso N. Notch-dependent repression of miR-155 in the bone marrow niche regulates hematopoiesis in an NF-κB-dependent manner. Cell Stem Cell 15(1):51-65, 7/2014. PMID: 24996169.
8. Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan-Halevy I, Ferrajoli A, Burger JA, O'Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 123(24):3797-802, 6/2014. e-Pub 4/2014. PMCID: PMC4055926.
9. DiNardo CD, Daver N, Jain N, Pemmaraju N, Bueso-Ramos C, Yin CC, Pierce S, Jabbour E, Cortes JE, Kantarjian HM, Garcia-Manero G, Verstovsek S. Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia 28(4):958-61, 4/2014. e-Pub 1/2014. PMCID: PMC3981947.
10. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, Gattoni E, Pieri L, Guglielmelli P, Elena C, He S, Contel N, Mookerjee B, Sandor V, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer 120(4):513-20, 2/2014. e-Pub 10/2013. PMID: 24258498.
11. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, Levy R, Siulnik A, Gupta V, Khan M, DiPersio JF, McQuitty M, Catalano JV, Hunter DS, Knoops L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica 99(2):292-8, 2/2014. e-Pub 8/2013. PMCID: PMC3912959.
12. Santos FP, Tam CS, Kantarjian H, Cortes J, Thomas D, Pollock R, Verstovsek S. Splenectomy in patients with Myeloproliferative Neoplasms: efficacy, complications and impact on survival and transformation. Leuk Lymphoma 55(1):121-7, 1/2014. e-Pub 5/2013. PMCID: PMC3874259.
13. Pemmaraju N, Chang E, Daver N, Patel K, Jorgensen J, Sabloff B, Verstovsek S, Borthakur G. Extramedullary acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature. Front Oncol 4:130, 2014. e-Pub 6/2/2014. PMCID: PMC4040935.
14. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98(12):1865-71, 12/2013. e-Pub 9/2013. PMCID: PMC3856961.
15. Sever M, Quintás-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S. Signifi cance of Cytogenetic Abnormalities in Patients with Polycythemia Vera. Leuk Lymphoma 54(12):2667-70, 12/2013. e-Pub 4/2013. PMCID: PMC3815965.
16. Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J. Similar Outcome of Patients With Chronic Myeloid Leukemia Treated With Imatinib in or Out of Clinical Trials. Clin Lymphoma Myeloma Leuk 13(6):693-9, 12/2013. e-Pub 9/20/2013. PMCID: PMC3835390.
17. Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek S. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood 122(23):3784-6, 11/2013. e-Pub 9/2013. PMCID: PMC3952679.
18. Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S. Modest activity of pomalidomide in patients with myelofibrosis and significant anemia. Leuk Res 37(11):1440-4, 11/2013. e-Pub 7/2013. PMCID: PMC4232180.
19. Cherry M, Cardenas-Turanzas M, Pham H, Kantarjian H, Cortes J, Pierce S, Zhou L, Verstovsek S. Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome. Leuk Res 37(11):1472-6, 11/2013. e-Pub 8/2013. PMCID: PMC3818458.
20. Sampath D, Malik A, Plunkett W, Nowak B, Williams B, Burton M, Verstovsek S, Faderl S, Garcia-Manero G, List AF, Sebti S, Kantarjian HM, Ravandi F, Lancet JE. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res 37(11):1461-7, 11/2013. e-Pub 8/2013. PMCID: PMC4205589.
21. Nazha A, Estrov Z, Cortes J, Bueso-Ramos CE, Kantarjian H, Verstovsek S. Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis. Leuk Lymphoma 54(11):2537-9, 11/2013. e-Pub 2/2013. PMCID: PMC4135587.
22. Hu S, Bueso-Ramos CE, Verstovsek S, Miranda RN, Yin CC, McDonnell T, Medeiros LJ, Lin P. Metastatic Splenic Angiosarcoma Presenting With Thrombocytopenia and Bone Marrow Fibrosis Mimicking Idiopathic Thrombocytopenic Purpura and Primary Myelofibrosis: A Diagnostic Challenge. Clin Lymphoma Myeloma Leuk 13(5):629-33, 10/2013. e-Pub 6/22/2013. PMID: 23800601.
23. Jain P, Lin P, Bueso-Ramos C, Verstovsek S, Pemmaraju N. Primary autoimmune myelofibrosis (MF) with high grade peripheral T cell lymphoma (PTCL) NOS. Eur J Haematol 91(4):378-9, 10/2013. e-Pub 7/15/2013. PMID: 23772772.
24. Fu B, Ok CY, Goswami M, Xei W, Jaso JM, Muzzafar T, Bueso-Ramos C, Verstovsek S, Garcia-Manero G, Medeiros LJ, Wang SA. The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol 92(10):1335-43, 10/2013. e-Pub 5/10/2013. PMCID: PMC4190057.
25. Daver N, Vega-Ruiz A, Kantarjian HM, Estrov Z, Ferrajoli A, Kornblau S, Verstovsek S, Garcia-Manero G, Cortes JE. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl) 22(5):605-11, 9/2013. e-Pub 5/2013. PMCID: PMC3745781.
26. Mesa RA, Silver RT, Verstovsek S, Mascarenhas J, Kessler CM, Rondelli D, Goldberg JD, Marchioli R, Demakos EP, Silverman LR, Hoffman R. Single agent Bevacizumab for myelofibrosis: results of the Myeloproliferative disorders-Research Consortium Trial. Haematologica 98(9):1421-3, 9/2013. e-Pub 6/2013. PMCID: PMC3762099.
27. Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a. Blood 122(6):893-901, 8/2013. e-Pub 6/2013. PMCID: PMC3739035.
28. Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J. Outcome After Failure of Second Generation Tyrosine Kinase Inhibitors Treatment As First-line Therapy for Patients With Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(4):477-84, 8/2013. e-Pub 6/14/2013. PMCID: PMC3752280.
29. Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S. Progressive burden of myelofibrosis in untreated patients: Assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study. Leuk Res 37(8):911-6, 8/2013. e-Pub 5/2013. PMID: 23684482.
30. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, Gotlib J, Dupriez B, Pardanani A, Harrison C, Hoffman R, Gisslinger H, Kröger N, Thiele J, Barbui T, Barosi G. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European LeukemiaNet (ELN) consensus report. Blood 122(8):1395-8, 8/2013. e-Pub 7/2013. PMID: 23838352.
31. Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J. Early responses predicts for better outcomes in patients with newly diagnosed CML: results with four TKI modalities. Blood 121(24):4867-74, 6/2013. e-Pub 4/2013. PMCID: PMC3743466.
32. Quintás-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S. Prognostic Model to Identify Patients With Myelofibrosis at the Highest Risk of Transformation to Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 13(3):315-318.e2, 6/2013. e-Pub 2/4/2013. PMCID: PMC3901422.
33. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project. Blood 121(23):4778-81, 6/2013. e-Pub 4/2013. PMCID: PMC3674675.
34. Takahashi K, Cortes J, Pierce S, Abruzzo L, Kantarjian H, Verstovsek S. Chromosome 5q deletion is extremely rare in patients with myelofibrosis. Leuk Res 37(5):552-5, 5/2013. e-Pub 2/2013. PMID: 23391517.
35. Fiskus W, Verstovsek S, Manshouri T, Smith JE, Peth K, Abhyankar S, McGuirk J, Bhalla KN. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther 12(5):577-88, 5/2013. e-Pub 2/2013. PMID: 23445613.
36. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor V, Kantarjian HM. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. Br J Haematol 161(4):508-16, 5/2013. e-Pub 3/11/2013. PMCID: PMC4055021.
37. Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TC. Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples. Genet Test Mol Biomarkers 17(5):429-37, 5/2013. e-Pub 3/28/2013. PMID: 23537216.
38. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial. J Clin Oncol 31(10):1285-92, 4/1/2013. e-Pub 2/19/2013. PMID: 23423753.
39. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Arock M, Sotlar K, Horny HP, Metcalfe DD, Escribano L, Verstovsek S, Tefferi A, Valent P. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121(13):2393-401, 3/2013. e-Pub 1/2013. PMCID: PMC3612852.
40. Wang SA, Hutchinson L, Tang G, Chen SS, Miron PP, Huh YO, Jones DM, Bueso-Ramos C, Verstovsek S, Medeiros LJ, Miranda RN. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol. e-Pub 1/18/2013. PMID: 23335446.
41. Jain P, Verstovsek S, Orlowski RZ, Yap E, Amin HM. An Unusual Case of Aggressive Systemic Mastocytosis With Associated Refractory Plasma Cell Myeloma. Clin Lymphoma Myeloma Leuk 12(6):459-62, http://www.sciencedirect.com/science/article/pii/S2152265012001474, 12/2012. e-Pub 9/2012. PMID: 23009979.
42. Benjamini O, Jain P, Estrov Z, Kantarjian HM, Verstovsek S. Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly. Blood 120(13):2768-9, 9/2012. PMID: 23019204.
43. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, Pierce S, Jabbour E, Borthakur G, Rumi E, Pungolino E, Morra E, Caramazza D, Cazzola M, Passamonti F. Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 120(6):1202-9, 8/2012. e-Pub 6/2012. PMID: 22718840.
44. Cheng X, Quintás-Cardama A, Golemovic M, Zingaro R, Gao MZ, Freireich EJ, Andreeff M, Kantarjian HM, Verstovsek S. The Organic Arsenic Derivative GMZ27 Induces PML-RARα-Independent Apoptosis in Myeloid Leukemia Cells. Anticancer Res 32(7):2871-80, 7/2012. PMID: 22753750.
45. Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gönen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S. Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms reveals recurrent SRSF2 mutations which are associated with adverse outcome. Blood 119(19):4480-5, 5/2012. PMCID: PMC3362363.
46. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 119(20):4614-8, 5/2012. e-Pub 3/2012. PMID: 22422826.
47. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger M, Miller C, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Koumenis IL, Sun W, Sandor V, Kantarjian HM. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799-807, 3/2012. PMID: 22375971.
48. Cortes J, Quintas-Cardama A, Jabbour E, O'Brien S, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Burton E, Shan J, Kantarjian H. The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint? Clin Lymphoma Myeloma Leuk 11(5):421-6, 10/2011. e-Pub 8/2011. PMCID: PMC3215673.
49. Jabbour E, Thomas D, Kantarjian H, Zhou L, Pierce S, Cortes J, Verstovsek S. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis. Blood 118(4):899-902, 7/2011. e-Pub 5/2011. PMID: 21622644.
50. Manshouri T, Estrov Z, Quintás-Cardama A, Burger J, Zhang Y, Livun A, Knez L, Harris D, Creighton CJ, Kantarjian HM, Verstovsek S. Bone Marrow Stroma Secreted Cytokines Protect JAK2V617F-Mutated Cells From the Effects of a JAK2 Inhibitor. Cancer Res 71(11):3831-40, 6/2011. e-Pub 4/2011. PMID: 21512135.
51. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. What are RBC-transfusion-dependence and -independence? Leuk Res 35(1):8-11, 1/2011. e-Pub 8/2010. PMID: 20692036.
52. Al-Kali A, Verstovsek S, Kantarjian H, Luthra R, Cortes J. Competing cell clones in myeloproliferative neoplasm. Blood 116(23):5074-5, 12/2010. PMID: 21127188.
53. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, Estrov Z, Fridman JS, Bradley EC, Erickson-Viitanen S, Vaddi K, Levy R, Tefferi A. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N Engl J Med 363(12):1117-27, 9/16/2010. PMID: 20843246.

Editorials

1. Van Roosbroeck K, Verstovsek S, Calin GA. Long non-coding rnas in primary myelofibrosis: the dark matter in hematopoietic progenitor cells? Leuk Lymphoma. e-Pub 8/2014. PMID: 25093380.
2. Daver N, Verstovsek S. Ruxolitinib and DNA methyltransferase-inhibitors: A foray into combination regimens in myelofibrosis. Leuk Lymphoma. e-Pub 7/2014. PMID: 24913500.
3. Verstovsek S. Changing myelofibrosis's natural course at last. Blood 123(12):1776-7, 3/2014. PMID: 24652960.
4. Verstovsek S. Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis. Leuk Lymphoma 55(1):5-6, 1/2014. e-Pub 8/2013. PMID: 23829281.
5. Verstovsek S. Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival. Oncology (Williston Park) 27(7):717-8, 7/2013. PMID: 23977769.
6. Cortés JE, Freireich EJ, Kantarjian H, Verstovsek S. Retrospect of hematologic malignancies 2010. Clin Lymphoma Myeloma Leuk 11 Suppl 1:S1, 6/2011. e-Pub 5/2011. PMID: 22035736.
7. Verstovsek S. Janus-Activated Kinase 2 Inhibitors: A New Era of Targeted Therapies Providing Significant Clinical Benefit for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. J Clin Oncol 29(7):781-3, 3/2011. e-Pub 1/2011. PMID: 21220594.
Other Articles
1. Verstovsek S, Komrokji RS. Novel and emerging therapies for the treatment of polycythemia vera. Expert Rev Hematol. e-Pub 10/29/2014. PMID: 25353086.
2. Santos FP, Verstovsek S. Efficacy of ruxolitinib for myelofibrosis. Expert Opin Pharmacother 15(10):1465-73, 7/2014. e-Pub 5/24/2014. PMID: 24856675.
3. Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, Verstovsek S. Practical management of patients with myelofibrosis receiving ruxolitinib. Expert Rev Hematol 6(5):511-23, 10/2013. e-Pub 10/2/2013. PMID: 24083419.
4. Verstovsek S, Almomen AK, Newberry K, Aleem A. Development of ruxolitinib as a myelofibrosis therapy. Journal of Applied Hematology 4(3):89-95, 9/2013.
5. Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Investig Drugs 22(6):687-99, 6/2013. e-Pub 2/23/2013. PMID: 23432430.
6. Quintás-Cardama A, Verstovsek S. Molecular Pathways: JAK/STAT PATHWAY: MUTATIONS, INHIBITORS, AND RESISTANCE. Clin Cancer Res 19(8):1933-40, 4/15/2013. e-Pub 2/13/2013. PMID: 23406773.
7. Santos FP, Verstovsek S. What is next beyond janus kinase 2 inhibitors for primary myelofibrosis? Curr Opin Hematol 20(2):123-9, 3/2013. PMID: 23385614.
8. Verstovsek S. Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol 90(2):89-98, 2/2013. e-Pub 11/2012. PMCID: PMC3761194.
9. Lee HJ, Daver N, Kantarjian HM, Verstovsek S, Ravandi F. The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clin Cancer Res 19(2):327-335, 1/15/2013. e-Pub 12/3/2012. PMID: 23209034.
10. Verstovsek S. Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. Postgrad Med 125(1):128-35, 1/2013. PMID: 23391678.
11. Komrokji R, Verstovsek S. Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Rev Hematol 5(6):631-41, 12/2012. PMID: 23216593.
12. Atallah E, Verstovsek S. Emerging drugs for myelofibrosis. Expert Opin Emerg Drugs 17(4):555-70, 12/2012. PMID: 23186315.
13. Komrokji RS, Verstovsek S, Padron E, List AF. Advances in the management of myelofibrosis. Cancer Control 19(4 Suppl):4-15, 10/2012. PMID: 23042420.
14. Santos FP, Verstovsek S. Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 26(5):1083-99, 10/2012. e-Pub 8/2012. PMID: 23009939.
15. Verstovsek S. Development and Clinical Use of a New Therapy for Myelofibrosis: Oral Ruxolitinib. Treatment Strategies – Hematology 2(2):61-65, http://viewer.zmags.com/publication/00ea2be3#/00ea2be3/61, 9/2012.
16. Randhawa J, Ostojic A, Vrhovac R, Atallah E, Verstovsek S. Splenomegaly in myelofibrosis--new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors. J Hematol Oncol 5(1). e-Pub 8/2012. PMID: 22852872.
17. Mascarenhas J, Mughal TI, Verstovsek S. Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib. Curr Med Chem 19(29). e-Pub 7/2012. PMCID: PMC3480698.
18. Santos FP, Verstovsek S. JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation? Anticancer Agents Med Chem 12(9). e-Pub 5/2012. PMID: 22583424.
19. Quintás-Cardama A, Verstovsek S. Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms. Cancer 118(4):870-7, 2/2012. e-Pub 7/2011. PMID: 21766300.
20. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Ther Clin Risk Manag 8:95-103, 2012. e-Pub 3/2012. PMCID: PMC3295626.
21. Quintás-Cardama A, Jain N, Verstovsek S. Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis. Cancer 117(24):5439-49, 12/2011. e-Pub 6/2011. PMID: 21692073.
22. Ostojic A, Vrhovac R, Verstovsek S. Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis. Future Oncol 7(9):1035-43, 9/2011. PMID: 21919691.
23. Naqvi K, Verstovsek S, Kantarjian H, Ravandi F. A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs 20(8):1159-66, 8/2011. e-Pub 6/2011. PMID: 21635221.
24. Quintás-Cardama A, Verstovsek S. New JAK2 inhibitors for myeloproliferative neoplasms. Expert Opin Investig Drugs 20(7):961-72, 7/2011. e-Pub 4/2011. PMID: 21521147.
25. Santos FP, Verstovsek S. JAK2 Inhibitors: Are They the Solution? Clin Lymphoma Myeloma Leuk 11 Suppl 1:S28-36, 6/2011. e-Pub 5/4/2011. PMID: 22035745.
26. Santos FP, Verstovsek S. JAK2 inhibitors: What's the true therapeutic potential? Blood Rev 25(2):53-63, 3/2011. e-Pub 11/2010. PMID: 21095048.
27. Agrawal M, Garg RJ, Cortes J, Kantarjian H, Verstovsek S, Quintas-Cardama A. Experimental therapeutics for patients with myeloproliferative neoplasias. Cancer 117(4):662-76, 2/2011. e-Pub 10/2010. PMID: 20922795.
28. Verstovsek S. Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis. Clin Cancer Res 16(7):1988-96, 4/2010. e-Pub 3/2010. PMID: 20215535.
29. Verstovsek S. Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders. Leuk Res 33(5):617-23, 5/2009. e-Pub 11/2008. PMID: 19013641.
30. Atallah E, Verstovsek S. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms. Expert Rev Anticancer Ther 9(5):663-70, 5/2009. PMID: 19445582.

Abstracts

1. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rumi E, Gattoni E, Pieri L, Zhang H, Cazzola M, Kantarjian HM, Barbui T, Vannucchi AM. Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea. Blood 124(21) (#1847), 12/2014.
2. Verstovsek S, Mesa RA, Foltz LM, Gupta V, Mascarenhas JO, Ritchie EK, Hoffman R, Silver RT, Kremyanskaya M, Pozdnyakova O, Hasserjian RP, Trehu E, Kantarjian HM, Gotlib JR. Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. Blood 124(21) (#713), 12/2014.
3. Daver N, Cortes JE, Jabbour E, Pemmaraju N, Jain N, Estrov Z, Kornblau SM, Burger JA, Kantarjian HM, Newberry KJ, Verstovsek S. Ruxolitinib and Lenalidomide As a Combination Therapy for Patients with Myelofibrosis. Blood 124(21) (#1831), 12/2014.
4. Verstovsek S, Kiladjian JJ, Mesa R, Jones MM, He S, Li J, Habr D, Vannucchi AM. Ruxolitinib Efficacy By Hematocrit Control in Patients with Polycythemia Vera: An Analysis of the RESPONSE Trial. Blood 124(21) (#3201), 12/2014.
5. Shastri A, Cortes JE, Jabbour EJ, Zhou L, Schroeder K, Kantarjian HM, Verstovsek S. A Phase II Study of Low-Dose Pomalidomide (0.5mg/day) and Prednisone Combination Therapy in Patients with Myelofibrosis and Significant Anemia. Blood 120(21) (#1728), 11/2012.
6. Verstovsek S, Kiladjian J, Mesa RA, Vannucchi AM, Gotlib J, Barosi G, Kantarjian HM, Sirulnik A, Peng W, Sandor VA, Harrison CN. Effect of Ruxolitinib On the Incidence of Splenectomy in Patients with Myelofibrosis: A Retrospective Analysis of Data From Ruxolitinib Clinical Trials. Blood 120(21) (#2847), 11/2012.
7. Talpaz M, Paquette R, Afrin L, Hamburg S, Jamieson K, Terebelo H, Ortega G, Lyons R, Tiu RV, Winton EF, Natrajan K, Odenike O, Peng W, SandorVA, O'Neill P, Erickson-Viitanen S, Leopold L, Levy RS, Kantarjian HM, Verstovsek S. Efficacy, Hematologic Effects, and Dose of Ruxolitinib in Myelofibrosis Patients with Low Starting Platelet Counts (50-100 x 109/L): A Comparison to Patients with Normal or High Starting Platelet Counts. Blood 120(21) (#176), 11/2012.
8. Mesa RA, Verstovsek S, Gupta V, Mascarenhas J, Atallah E, Sun W, Sandor VA, Gotlib J. Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I. Blood 120(21) (#1733), 11/2012.
9. Pemmaraju N, Kantarjian HM, Cortes JE, Quintas-Cardama A, Pierce SA, Verstovsek S. Incidence and Outcomes of Myeloproliferative Neoplasms (MPN) in Adolescents and Young Adults (AYAs). Blood 120(21) (#2845), 11/2012.
10. Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen P, He S, Contel N, Mookerjee B, Rumi E, Gattoni E, Pieri L, Cazzola M, Kantarjian H, Barbui T, Vannucchi A. Long-Term Efficacy and Safety Results From a Phase II Study of Ruxolitinib in Patients with Polycythemia Vera. Blood 120(21) (#804), 11/2012.
11. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, Catalano JV, Deininger MWN, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey, Jr. JH, Arcasoy MO, Hexner EO, Lyons R, Paquette R, Raza A, Vaddi K, Erickson-Viitanen S, Sun W, Sandor VA, Kantarjian HM. Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. Blood 120(21) (#800), 11/2012.
12. Pemmaraju N, Kantarjian HM, O'Brien S, Kadia TM, Cortes JE, Borthakur G, Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Quintas-Cardama A, Jabbour EJ, Koller CA, Dellasala SE, Pierce SA, Burton EM, Verstovsek S. Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia. Blood 120(21) (#3617), 11/2012.
13. Santos FPS, Tam CS, Kantarjian HM, Cortes JE, Thomas DA, Pollock RE, Verstovsek S. Splenectomy in Patients with Myeloproliferative Neoplasms (MPNs): Efficacy, Complications and Impact On Survival and Transformation. Blood 120(21) (#2853), 11/2012.

Book Chapters

1. Santos FPS, Verstovsek S. Myelofibrosis. In: Emerging Cancer Therapeutics: Leukemia. 2, 2. Ed(s) Popat U. Demos Medical Publishing: New York, 307-328, 2011.
2. Verstovsek S. Therapeutic potential of JAK2 inhibitors. In: Hematology Am Soc Hematol Educ Program, 636-42, 2009. ISBN: 20008249.

Grant & Contract Support

Title: SCOR: Deciphering and Targeting Clonal Evolution in Hematologic Malignancies; Project 2: Molecular Pathogenesis and Therapy of Transformation from MPN to AML
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator-MDACC
Principal Investigator: Irene Ghobrial, MD, Dana Farber PI, Ross Levine project leader MSKCC (SK co-PI)
Duration: 10/1/2013 - 9/30/2018

Last updated: 4/14/2015